Cocrystal Pharma, Inc. (NASDAQ:COCP) Short Interest Update

Cocrystal Pharma, Inc. (NASDAQ:COCP) saw a large decline in short interest in April. As of April 15th, there was short interest totalling 1,500 shares, a decline of 70.0% from the March 31st total of 5,000 shares. Based on an average daily volume of 13,900 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the company’s stock are sold short.

Cocrystal Pharma Price Performance

Cocrystal Pharma stock traded up $0.04 during mid-day trading on Friday, reaching $1.56. The stock had a trading volume of 29,490 shares, compared to its average volume of 13,389. The company has a market capitalization of $15.81 million, a price-to-earnings ratio of -0.78 and a beta of 1.34. The company has a 50-day moving average price of $1.49 and a two-hundred day moving average price of $1.63. Cocrystal Pharma has a one year low of $1.33 and a one year high of $3.29.

Cocrystal Pharma (NASDAQ:COCP) last posted its earnings results on Thursday, March 28th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.13. On average, equities research analysts anticipate that Cocrystal Pharma will post -2.31 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Cocrystal Pharma in a research note on Thursday, April 4th.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections.